The purpose of this study is to explore the detection of circulating tumor DNA, soluble
immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled
to undergo systemic therapy. In this study we will utilize a novel technology for
circulating tumor DNA detection in order to evaluate their presence in patients with lung
cancer by comparing blood samples at six time points. We will obtain baseline blood and then
collect blood at five time points during the course of the patient's chemotherapy treatments
and at the end of treatment. These same blood collections will be used for the detection of
soluble immune markers and evaluation of PBMCs.
- Advanced (non-resectable) malignancy in the thorax
- Age >18 years old
- Willing and able to provide consent
- No prior history of neoadjuvant therapy
- Age <18 years old
- Unable to provide consent
- Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential